KCM
SYRE icon

Kennedy Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Kennedy Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Buy
17,310
+437
+3% +$31.9K 0.03% 476
2026
Q1 		$851K Buy
+16,873
New +$636K 0.02% 498

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Kennedy Capital Management's SYRE Position: Q2 2026 in Review

Kennedy Capital Management increased its Spyre Therapeutics (SYRE) stake by 2.6% in Q2 2026, buying an estimated $31.9K and bringing the position to 17,310 shares worth $1.54M. The position accounts for 0.03% of the portfolio, ranked #476.

Kennedy Capital Management first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Kennedy Capital Management held 17,310 shares of Spyre Therapeutics worth $1.54M as of Q2 2026.
  • Kennedy Capital Management bought 437 Spyre Therapeutics shares in Q2 2026, an estimated $31.9K.
  • Spyre Therapeutics made up 0.03% of Kennedy Capital Management's portfolio in Q2 2026, its #476 holding.
  • Kennedy Capital Management first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.